BioPharmSignal logoBioPharmSignal

Biotech News

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

Lexicon Pharmaceuticals (LXRX)Lexicon PharmaceuticalsEarnings

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Related news

LXRXLexicon Pharmaceuticals2026-07-30 12:30 EST

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

ALTAltimmune2026-11-05 13:00 EST

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

RYTMRhythm Pharmaceuticals2026-11-03 12:00 EST

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

MNKDMannKind2026-10-29 20:01 EST

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

MLYSMineralys Therapeutics2026-10-28 20:05 EST

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Lexicon Pharmaceuticals

Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases. Sotagliflozin Franchise Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application...

Recent company news

LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

LXRXLexicon Pharmaceuticals2026-10-23 12:30 EST

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

LXRXLexicon Pharmaceuticals2026-10-21 12:30 EST

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

LXRXLexicon Pharmaceuticals2026-09-01 20:05 EST

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

LXRXLexicon Pharmaceuticals2026-08-31 12:30 EST

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Stock data

Close
1.61 USD
Market cap
839.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States